The European Union has awarded €5.4 million in financing to a University College Cork-led research initiative that aims to revolutionize Crohn’s disease treatment (EU).

Crohn’s disease (CD) is a chronic inflammation of the bowel with few treatment options. It affects up to 3 million people in Europe and costs the healthcare system more than 5 billion euros yearly.

GENEGUT, a four-year research project directed by UCC’s School of Pharmacy in collaboration with APC Microbiome Ireland SFI Research Centre at UCC and financed by Horizon Europe, is now in the process of developing the first oral RNA-based medication for ileal Crohn’s Disease.

Prof. Caitriona O’Driscoll Project Coordinator of GENEGUT and her team from the UCC’s School of Pharmacy and APC Microbiome Ireland. GENEGUT is a new innovative EU-funded research project changing the treatment paradigm for Crohn’s Disease patients with a new orally administered RNA-based advanced therapy (FLTR: Dr. Piotr Kowalski, Dr. Jospeh O’Shea, Prof. Caitriona O’Driscoll, Dr. Patrick O’Dwyer) – (Missing: Prof. Subrata Ghosh, Prof. Brendan Griffin, Dr. Ken Nally. Dr. Silvia Melgar) Daragh Mc Sweeney/Provision

Read more in the original article below.